12:00 AM
 | 
Dec 05, 2011
 |  BC Week In Review  |  Company News  |  Deals

Infinity, Mundipharma deal

Mundipharma elected to further extend by one year a 2008 deal to fund development of Infinity's IPI-145 as well as other candidates arising from Infinity's discovery programs against phosphoinositide 3-kinase (PI3K). Mundipharma committed over $50 million in funding in 2013. In December 2010, Mundipharma...

Read the full 216 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >